M&A – Talk Bio

Actionable Insights Powered by AI

Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans

2 months ago talkbio0Tagged Acelyrin, Alumis, biopharmaceutical industry, Concentra Biosciences, Disruption, M&A, Merger, Unsolicited Adverse Event

Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A

J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

2 months ago talkbio0Tagged Acquisition, Caplyta, Drug Industry, Duato, Intra-Cellular Therapies, Joaquin, Johnson and Johnson, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

3 months ago talkbio0Tagged Acquisition, Biopharma, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A

Biotech Industry’s Turbulent Year: Fierce Biotech’s Top 10 Most-Read Stories of 2024

4 months ago talkbio0Tagged Biopharma, biotech industry, J.P. Morgan Healthcare, M&A, rejections, shutdowns, trends qualifier, United States Food and Drug Administration

Biotech industry, layoffs, site shutdowns, FDA rejections, M&A deals, J.P. Morgan Healthcare Conference, biopharma trends

Navigating JPM Week 2024: Insights and Opportunities in Biopharma

5 months ago talkbio0Tagged Biopharma, deal-making, Industry, Investments, IPOs, JPM, M&A, Network, regulatory, trends qualifier

JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

5 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A

6 months ago talkbio0Tagged Biopharma, Health care facility, Jr., M&A, Robert F. Kennedy Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.

Roche Accelerates Obesity Drug Development and Explores M&A Opportunities

9 months ago talkbio0Tagged Drug Development, M&A, Obesity, Roche (company)

Roche, obesity drugs, M&A, pharmaceuticals, drug development

AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio

10 months ago talkbio0Tagged AbbVie, Acquisition (action), biotech, degrees Celsius, Inflammatory disorder, M&A

AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech